Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamin H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83
Article
CAS
PubMed
Google Scholar
Yang Y, Lewis J, Epstein S et al (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc 296:2947–2953
Article
CAS
Google Scholar
Targownik LE, Lix LM, Metge CJ et al (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 179:319–326
Article
Google Scholar
Yu EW, Blackwell T, Ensrud KE et al (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259
Article
CAS
PubMed
PubMed Central
Google Scholar
Voelker R (2010) Proton pump inhibitors linked to fracture risk. J Am Med Assoc 304:29
Article
CAS
Google Scholar
Maes ML, Fixen DR, Linnebur SA (2017) Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf 8:273–297
Article
CAS
PubMed
PubMed Central
Google Scholar
Skjødt MK, Ostadahmadli Y, Abrahamsen B (2019) Long term time trends in use of medications associated with risk of developing osteoporosis: nationwide data for Denmark from 1999 to 2016. Bone 120:94–100
Article
PubMed
Google Scholar
Rotman S, Bishop T (2013) Proton pump inhibitor use in the US ambulatory setting, 2002–2009. PLoS ONE 8:e56060
Article
CAS
PubMed
PubMed Central
Google Scholar
Wallerstedt S, Fastbom J, Linke J et al (2017) Long-term use of proton pump inhibitors and prevalence of disease-related and drug-related reasons for gastroprotection—a cross-sectional population-based study. Pharmacoepidemiol Drug Saf 26:9–16
Article
CAS
PubMed
Google Scholar
Hussain S, Siddiqui AN, Habib A et al (2018) Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int 38:1999–2014
Article
PubMed
Google Scholar
Poly TN, Islam MM, Yang HC et al (2019) Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 30:103–114
Article
CAS
PubMed
Google Scholar
Liu J, Li X, Fan L et al (2019) Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis. Life Sci 218:213–223
Article
CAS
PubMed
Google Scholar
Thong BKS, Ima-Nirwana S, Chin KY (2019) Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health 16:1571
Article
CAS
PubMed Central
Google Scholar
Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28:951–959
Article
CAS
PubMed
Google Scholar
Harding BN, Weiss NS, Walker RL et al (2018) Proton pump inhibitor use and the risk of fractures among an older adult cohort. Pharmacoepidemiol Drug Saf 27:596–603
Article
CAS
PubMed
PubMed Central
Google Scholar
Chiu H, Huang Y, Chang C et al (2010) Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 19:1131–1136
Article
PubMed
Google Scholar
Adams AL, Black MH, Zhang JL et al (2014) Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol 24:286–290
Article
PubMed
Google Scholar
Fraser LA, Leslie WD, Targownik LE et al (2013) The effect of proton pump inhibitors on fracture risk: report from the Canadian multicenter osteoporosis study. Osteoporos Int 24:1161–1168
Article
CAS
PubMed
Google Scholar
Khalili H, Huang ES, Jacobson BC et al (2012) Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. Br Med J 344:e372
Article
CAS
Google Scholar
Yu EW, Bauer SR, Bain PA et al (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124:519–526
Article
CAS
PubMed
PubMed Central
Google Scholar
DVO (2017) Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern. Leitlinie des Dachverbandes der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e. V. 2017. http://www.dv-osteologie.org/dvo_leitlinien/dvo-leitlinie-2017, S. 80–81. Zugegriffen: 5.10.2019
Abramowitz J, Thakkar P, Isa A et al (2016) Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews. Otolaryngol Head Neck Surg 155:547–554
Article
PubMed
Google Scholar
Targownik LE, Lix LM, Leung S et al (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904
Article
CAS
PubMed
Google Scholar
Targownik LE, Leslie WD, Davison KS et al (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian multicentre osteoporosis study (CaMos). Am J Gastroenterol 107:1361–1369
Article
PubMed
PubMed Central
Google Scholar
Targownik LE, Goertzen AL, Luo Y et al (2017) Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol 112:95–101
Article
CAS
PubMed
Google Scholar
Maggio M, Lauretani F, Ceda GP et al (2013) Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57:437–442
Article
CAS
PubMed
PubMed Central
Google Scholar
Shin YH, Gong HS, Baek GH (2019) Lower trabecular bone score is associated with the use of proton pump inhibitors. J Clin Densitom 22:236–242
Article
PubMed
Google Scholar
Jacob L, Hadji P, Kostev K (2016) The use of proton pump inhibitors is positively associated with osteoporosis in postmenopausal women in Germany. Climacteric 19:478–481
Article
CAS
PubMed
Google Scholar
O’Connell MB, Madden DM, Murray AM et al (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781
Article
CAS
PubMed
Google Scholar
Hansen KE, Nieves JW, Nudurupati S et al (2019) Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women. Gastroenterology 156:926–934
Article
CAS
PubMed
Google Scholar
Hartmann B, Donnelly-VanderLoo M, Watson T et al (2016) Proton-pump inhibitor therapy and vitamin B12 status in an inpatient hospital setting. Appl Physiol Nutr Metab 41:1071–1076
Article
CAS
Google Scholar
Hinson AM, Wilkerson BM, Rothman-Fitts I et al (2015) Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc 63:2070–2073
Article
PubMed
Google Scholar
Lewis JR, Barre D, Zhu K et al (2014) Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 29:2489–2497
Article
PubMed
Google Scholar
Cea-Soriano L, Johansson S, Garcia Rodriguez LA (2013) Risk factors for falls with use of acid-suppressive drugs. Epidemiology 24:600–607
Article
PubMed
Google Scholar
Lee J, Youn K, Choi NK et al (2013) A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 48:1016–1022
Article
CAS
PubMed
Google Scholar
Abrahamsen B, Eiken P, Eastell R (2011) Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 171:998–1004
PubMed
Google Scholar
Itoh S, Sekino Y, Shinomiya K et al (2013) The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab 31:206–211
Article
CAS
PubMed
Google Scholar
Nyandege AN, Slattum PW, Harpe SE (2015) Risk of fracture and the concomitant use of bisphosphonates with osteoporosis inducing medications. Ann Pharmacother 49:437–447
Article
CAS
PubMed
Google Scholar
Yang SD, Chen Q, Wei HK et al (2015) Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med 8:4899–4910
CAS
PubMed
PubMed Central
Google Scholar
Bartl R, von Tresckow E (2012) Interaktionen der Protonenpumpenhemmer mit oralen Bisphosphonaten und Frakturrisiko. Dtsch Med Wochenschr 137:804–805
Article
CAS
PubMed
Google Scholar
Panday K, Gona A, Humphrey MB (2014) Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis 6:185–202
Article
CAS
PubMed
PubMed Central
Google Scholar
Kendler DL, Marin F, Geusens P et al (2019) Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Bone 130:115113
Article
CAS
PubMed
Google Scholar